Senseonics (NYSE:SENS) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $2.00 target price on shares of Senseonics in a research report on Friday, November 15th.

Senseonics Stock Performance

Shares of SENS opened at $0.48 on Thursday. The stock has a market capitalization of $283.26 million, a PE ratio of -3.66 and a beta of 0.77. The business’s fifty day moving average price is $0.34 and its 200 day moving average price is $0.38. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. Senseonics has a 12-month low of $0.25 and a 12-month high of $0.75.

Insider Activity

In other news, CFO Frederick T. Sullivan bought 124,933 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $0.38 per share, with a total value of $47,474.54. Following the completion of the transaction, the chief financial officer now directly owns 2,478,844 shares in the company, valued at approximately $941,960.72. The trade was a 5.31 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Timothy T. Goodnow acquired 315,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was purchased at an average cost of $0.31 per share, with a total value of $97,650.00. Following the purchase, the chief executive officer now directly owns 11,310,355 shares in the company, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their position. The disclosure for this purchase can be found here. Insiders own 3.60% of the company’s stock.

Institutional Trading of Senseonics

Several institutional investors have recently made changes to their positions in SENS. Geode Capital Management LLC increased its position in Senseonics by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock worth $2,042,000 after purchasing an additional 179,103 shares during the last quarter. Symmetry Partners LLC bought a new stake in shares of Senseonics in the 3rd quarter valued at approximately $164,000. Cubist Systematic Strategies LLC increased its holdings in Senseonics by 25.9% in the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after buying an additional 85,501 shares during the last quarter. GSA Capital Partners LLP bought a new position in Senseonics during the third quarter valued at approximately $117,000. Finally, FMR LLC lifted its stake in Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after acquiring an additional 167,970 shares during the last quarter. 12.36% of the stock is currently owned by institutional investors and hedge funds.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.